Physician profile
Michael D Beitle
NPI 1659318392
$9,386.26
in general payments reported to CMS, 2019-2025
34 companies · $819 in 2025
The $819 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,856 · 2020: $871 · 2021: $1,805 · 2022: $1,843 · 2023: $1,458 · 2024: $735 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,913 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,913.03 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $994.71 | 2019-2022 | |
| Exeltis, USA INC. | $977.23 | 2020-2025 | Slynd, Tyblume |
| Pfizer INC. | $823.59 | 2019-2025 | |
| Abbvie INC. | $809.57 | 2020-2024 | Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $629.42 | 2019-2024 | Veozah, Myrbetriq |
| Celularity INC. | $600.00 | 2019 | |
| Myovant Sciences INC. | $510.76 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $503.20 | 2023-2025 | Myfembree, Gemtesa |
| Allergan, INC. | $463.27 | 2019-2020 | |
| Agile Therapeutics, INC. | $336.00 | 2021-2023 | Twirla |
| Mylan Pharmaceuticals INC. | $334.78 | 2021-2022 | |
| Caldera Medical, INC | $301.50 | 2022-2023 | Desara |
| Avion Pharmaceuticals | $247.50 | 2019-2021 | |
| Sage Therapeutics, LLC | $241.87 | 2024-2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $231.92 | 2021-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $220.43 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $132.61 | 2019-2021 | |
| Coopersurgical, INC. | $123.50 | 2019-2025 | Endosee, Summit Doppler |
| Lupin INC. | $119.95 | 2019-2020 | |
| Ethicon US, LLC | $116.63 | 2024-2025 | Enseal X1, Ethicon, Stratafix |
| Medicem INC. | $104.17 | 2020-2021 | |
| Hologic Sales and Service, LLC | $98.91 | 2019-2024 | Myosure Tissue Removal Device, Acessa Provu System |
| Vertex Pharmaceuticals Incorporated | $91.88 | 2025 | |
| Ascend Therapeutics US, LLC | $77.42 | 2022-2023 | |
| Scynexis, INC. | $63.15 | 2022 | |
| Organon LLC | $46.15 | 2022-2024 | Nexplanon |
| Boston Scientific Corporation | $35.10 | 2019 | |
| Supernus Pharmaceuticals, INC. | $32.55 | 2025 | Qelbree |
| Amag Pharmaceuticals, INC. | $28.41 | 2019 | |
| Exact Sciences Corporation | $24.24 | 2025 | |
| Channel Medsystems, INC. | $22.14 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.92 | 2025 | |
| Shield Therapeutics INC | $14.83 | 2023 | Accrufer |
| Ferring Pharmaceuticals INC. | $13.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Beitle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.